Comparative Pharmacology
Head-to-head clinical analysis: CLARAVIS versus TAZAROTENE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLARAVIS versus TAZAROTENE.
CLARAVIS vs TAZAROTENE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Isotretinoin, a retinoid, reduces sebum production, inhibits sebaceous gland activity, and normalizes follicular keratinization. It also exhibits anti-inflammatory effects.
Tazarotene is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RAR-β, RAR-γ) with high affinity, modulating gene expression involved in cell proliferation, differentiation, and inflammation.
Oral: 30 mg once daily after a meal for 12 weeks; administration with high-fat meal increases absorption.
Topical: Apply a pea-sized amount to affected areas once daily in the evening. For plaque psoriasis, use 0.05% or 0.1% gel or cream. For acne vulgaris, use 0.1% cream or 0.045% or 0.1% lotion.
None Documented
None Documented
Clinical Note
moderateTazarotene + Deferasirox
"The serum concentration of Deferasirox can be increased when it is combined with Tazarotene."
Clinical Note
moderateTazarotene + Teriflunomide
"The metabolism of Teriflunomide can be decreased when combined with Tazarotene."
Clinical Note
moderateTazarotene + Clotrimazole
"The metabolism of Clotrimazole can be decreased when combined with Tazarotene."
Clinical Note
moderateTazarotene + Nilotinib
Terminal half-life: 19-24 hours in adults; prolonged in renal impairment (up to 50 hours in ESRD).
Terminal elimination half-life of tazarotenic acid is 7–12 hours in healthy subjects; clinically, steady-state is achieved within 14 days.
Renal: 90% as unchanged drug; fecal: 5%; biliary: <1%.
Primarily fecal (approximately 60%) and urinary (approximately 13%) as metabolites; unchanged drug not detected in urine.
Category C
Category D/X
Retinoid
Retinoid
"The metabolism of Nilotinib can be decreased when combined with Tazarotene."